NanoViricides Inc(NNVC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.54 | Insider Own | 2.49% | Shs Outstand | 25.6M | Perf Week | -7.32% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 24.9M | Perf Month | -17.99% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | 0.23 | Inst Own | 9.1% | Short Float | 3.26% | Perf Quarter | -10.24% |
| Income | -0.01B | P/S | - | EPS this Y | -12.2% | Inst Trans | 2.17% | Short Ratio | 2.27 | Perf Half Y | -30.49% |
| Sales | 0.00B | P/B | 4.54 | EPS next 5Y | - | ROA | -135.9% | Short Interest | 0.81M | Perf YTD | 0.88% |
| Book/sh | 0.25 | P/C | 11.29 | EPS past 3/5Y | 18.01% 12.84% | ROE | -179.24% | 52W High | -40.93% ($1.93) | Perf Year | -8.06% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -189.89% | 52W Low | 34.12% ($0.85) | Perf 3Y | 0.01% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -5.19% | Gross Margin | - | Volatility(W/M) | 8.07% 7.39% | Perf 5Y | -75.16% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | -95.55% |
| Dividend Ex-Date | - | Quick Ratio | 0.95 | EPS Q/Q | -121.72% | Profit Margin | - | RSI (14) | 37.76 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.95 | Sales Q/Q | - | SMA20 | -13.67% ($1.32) | Beta | 1.83 | Target Price | $6 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -15.46% ($1.35) | Rel Volume | 0.3 | Prev Close | $1.17 |
| Employees | 7 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -10% - | SMA200 | -12.82% ($1.31) | Avg Volume(3M) | 0.36M | Price | $1.14 |
| IPO | 2004/8/12 | Option/Short | Yes/Yes | Trades | 248 | Volume | 106,808 | Change | -2.56% |
Nanoviricides (NNVC) is a clinical-stage biotech developing broad-spectrum antivirals that combine nanotechnology with a host-mimetic strategy. Its lead candidate, NV-387, has entered Phase II clinical trials targeting MPox (monkeypox) and respiratory viruses, and NV-HHV-1 for shingles is also part of the pipeline.
Over the past 1 year, roughly in the middle
41% below its 1-year high.
Traded less than usual. That is 30% of its average volume.
NNVC has weak earning power
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -12.2% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -75.2%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #438 of 598 in the industry
Based on market cap of $29M.
FAQ
NNVC belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of NNVC is approximately $29M, ranking 5,002 within its sector.
NNVC has recorded a 52-week high of $1.93 and a low of $0.85.